Omaveloxolone

Omaveloxolone
Clinical data
Trade names	Skyclarys
Other names	RTA 408
AHFS/Drugs.com	Monograph
License data	US DailyMed: Omaveloxolone;
Routes of; administration	By mouth
ATC code	N07XX25 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-1 1-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b- octadecahydropicen-4a-yl)-2,2-difluoropropanamide;
CAS Number	1474034-05-3 ;
PubChem CID	71811910;
IUPHAR/BPS	7573;
DrugBank	DB12513;
ChemSpider	34980948 ;
UNII	G69Z98951Q;
KEGG	D10964;
ChEBI	CHEBI:229661;
CompTox Dashboard (EPA)	DTXSID101138251 ;
Chemical and physical data
Formula	C33H44F2N2O3
Molar mass	554.723 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4C(\C#N)=C/[C@@]5(/C3=C/C(=O)[C@H]2[C@](CC[C@@]1(NC(=O)C(F)(F)C)CCC(C)(C)C[C@H]12)(C)[C@]3(C)CC[C@H]5C4(C)C)C;
	InChI InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1 ; Key:WPTTVJLTNAWYAO-KPOXMGGZSA-N ;
	(what is this?) (verify)

Omaveloxolone, sold under the brand name Skyclarys, is a medication used for the treatment of Friedreich's ataxia. It is taken by mouth.

The most common side effects include an increase in alanine transaminase and an increase of aspartate aminotransferase, which can be signs of liver damage, headache, nausea, abdominal pain, fatigue, diarrhea and musculoskeletal pain.

Omaveloxolone was approved for medical use in the United States in February 2023, and in the European Union in February 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.